{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:04:13Z","timestamp":1789340653920,"version":"build-2803163510"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Ultrasound"],"DOI":"10.1186\/s12947-026-00382-6","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:02:09Z","timestamp":1789340529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertrophic cardiomyopathy: state of the art on diagnosis and current therapeutic approach"],"prefix":"10.1186","volume":"24","author":[{"given":"Eluisa","family":"La Franca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lucchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla Elif","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italia","family":"Loddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Alioto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Fulvio","family":"Faletra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"5","key":"382_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","volume":"6","author":"BJ Maron","year":"2018","unstructured":"Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018;6(5):353\u201363. https:\/\/doi.org\/10.1016\/j.jchf.2017.09.011.","journal-title":"JACC Heart Fail"},{"issue":"37","key":"382_CR2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the Management of Cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"},{"key":"382_CR3","doi-asserted-by":"publisher","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy. Circulation. 2024;149(23). https:\/\/doi.org\/10.1161\/CIR.0000000000001250.","DOI":"10.1161\/CIR.0000000000001250"},{"issue":"4","key":"382_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10741-019-09775-4","volume":"24","author":"G Makavos","year":"2019","unstructured":"Makavos G, \u039aairis C, Tselegkidi M-E, Karamitsos T, Rigopoulos AG, Noutsias M, et al. Hypertrophic Cardiomyopathy: An Updated Review on Diagnosis, Prognosis, and Treatment. Heart Fail Rev. 2019;24(4):439\u201359. https:\/\/doi.org\/10.1007\/s10741-019-09775-4.","journal-title":"Heart Fail Rev"},{"key":"382_CR5","doi-asserted-by":"publisher","unstructured":"Maurizi N, Monda E, Biagini E, Field E, Passantino S, Dall\u2019 Aglio G, Fumagalli C, Antiochos P, Skalidis I, Pieroni M, Argir\u00f2 A, Girolami F, Cecchi F, Barbey F, Monney P, Elliott PM, Kaski JP, Limongelli G, Olivotto I. Hypertrophic cardiomyopathy: prevalence of disease-specific red flags. Eur Heart J. 2025;46(31):3082\u20133094. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf026.","DOI":"10.1093\/eurheartj\/ehaf026"},{"issue":"14","key":"382_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033200.","journal-title":"Circulation"},{"issue":"Suppl 5","key":"382_CR7","doi-asserted-by":"publisher","first-page":"v256","DOI":"10.1093\/eurheartjsupp\/suaf077","volume":"27","author":"C Chimenti","year":"2025","unstructured":"Chimenti C, Iacovoni A, Montalto A, Emdin M, Olivotto I, Basso C, et al. ANMCO Position Paper: Hypertrophic Cardiomyopathy\u2014From Diagnosis to Treatment. Eur Heart J Suppl. 2025;27(Suppl 5):v256\u201379. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suaf077.","journal-title":"Eur Heart J Suppl"},{"issue":"30","key":"382_CR8","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O\u2019Mahony","year":"2014","unstructured":"O\u2019Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A Novel Clinical Risk Prediction Model for Sudden Cardiac Death in Hypertrophic Cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30):2010\u201320. https:\/\/doi.org\/10.1093\/eurheartj\/eht439.","journal-title":"Eur Heart J"},{"issue":"1","key":"382_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/hrt.20.1.1","volume":"20","author":"D Teare","year":"1958","unstructured":"Teare D. Asymmetrical Hypertrophy of the Heart in Young Adults. Br Heart J. 1958;20(1):1\u20138. https:\/\/doi.org\/10.1136\/hrt.20.1.1.","journal-title":"Br Heart J"},{"issue":"17","key":"382_CR10","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2021.03.008","volume":"77","author":"H Cui","year":"2021","unstructured":"Cui H, Schaff HV, Lentz Carvalho J, Nishimura RA, Geske JB, Dearani JA, et al. Myocardial Histopathology in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021;77(17):2159\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2021.03.008.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"382_CR11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1161\/01.cir.63.4.882","volume":"63","author":"BJ Maron","year":"1981","unstructured":"Maron BJ, Anan TJ, Roberts WC. Quantitative Analysis of the Distribution of Cardiac Muscle Cell Disorganization in the Left Ventricular Wall of Patients with Hypertrophic Cardiomyopathy. Circulation. 1981;63(4):882\u201394. https:\/\/doi.org\/10.1161\/01.cir.63.4.882.","journal-title":"Circulation"},{"issue":"11","key":"382_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s11886-022-01778-2","volume":"24","author":"M Pieroni","year":"2022","unstructured":"Pieroni M, Ciabatti M, Saletti E, Tavanti V, Santangeli P, Martinese L, et al. Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies. Curr Cardiol Rep. 2022;24(11):1567\u201385. https:\/\/doi.org\/10.1007\/s11886-022-01778-2.","journal-title":"Curr Cardiol Rep"},{"issue":"9424","key":"382_CR13","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(04)16358-7","volume":"363","author":"P Elliott","year":"2004","unstructured":"Elliott P, McKenna WJ. Hypertrophic Cardiomyopathy. The Lancet. 2004;363(9424):1881\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(04)16358-7.","journal-title":"The Lancet"},{"issue":"12","key":"382_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/biom9120878","volume":"9","author":"P Teekakirikul","year":"2019","unstructured":"Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules. 2019;9(12):878. https:\/\/doi.org\/10.3390\/biom9120878.","journal-title":"Biomolecules"},{"issue":"9862","key":"382_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","volume":"381","author":"BJ Maron","year":"2013","unstructured":"Maron BJ, Maron MS. Hypertrophic Cardiomyopathy. The Lancet. 2013;381(9862):242\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(12)60397-3.","journal-title":"The Lancet"},{"issue":"10","key":"382_CR16","doi-asserted-by":"publisher","first-page":"e2021717118","DOI":"10.1073\/pnas.2021717118","volume":"118","author":"GG Repetti","year":"2021","unstructured":"Repetti GG, Kim Y, Pereira AC, Ingles J, Russell MW, Lakdawala NK, et al. Discordant Clinical Features of Identical Hypertrophic Cardiomyopathy Twins. Proc Natl Acad Sci. 2021;118(10):e2021717118. https:\/\/doi.org\/10.1073\/pnas.2021717118.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"382_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/eurheartj\/ehae747","volume":"46","author":"P Elliott","year":"2025","unstructured":"Elliott P, Schunkert H, Bondue A, Behr E, Carrier L, Van Duijn C, et al. Integration of Genetic Testing into Diagnostic Pathways for Cardiomyopathies: A Clinical Consensus Statement by the ESC Council on Cardiovascular Genomics. Eur Heart J. 2025;46(4):344\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehae747.","journal-title":"Eur Heart J"},{"issue":"1","key":"382_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41525-022-00288-y","volume":"7","author":"R Lesurf","year":"2022","unstructured":"Lesurf R, Said A, Akinrinade O, et al. Whole Genome Sequencing Delineates Regulatory, Copy Number, and Cryptic Splice Variants in Early Onset Cardiomyopathy. NPJ Genom Med. 2022;7(1):18. https:\/\/doi.org\/10.1038\/s41525-022-00288-y.","journal-title":"NPJ Genom Med"},{"issue":"7","key":"382_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.hrthm.2022.03.1225","volume":"19","author":"AAM Wilde","year":"2022","unstructured":"Wilde AAM, Semsarian C, M\u00e1rquez MF, et al. European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022;19(7):e1\u201360. https:\/\/doi.org\/10.1016\/j.hrthm.2022.03.1225.","journal-title":"Heart Rhythm"},{"issue":"9","key":"382_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","volume":"10","author":"RE Hershberger","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531\u201347. https:\/\/doi.org\/10.1038\/nrcardio.2013.105.","journal-title":"Nat Rev Cardiol"},{"key":"382_CR21","doi-asserted-by":"publisher","unstructured":"2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u20132779. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"382_CR22","doi-asserted-by":"publisher","first-page":"102281","DOI":"10.1016\/j.fsigen.2020.102281","volume":"47","author":"J Mates","year":"2020","unstructured":"Mates J, Mademont-Soler I, Fernandez-Falgueras A, et al. Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis? Forensic Sci Int Genet. 2020;47:102281. https:\/\/doi.org\/10.1016\/j.fsigen.2020.102281.","journal-title":"Forensic Sci Int Genet"},{"key":"382_CR23","doi-asserted-by":"publisher","unstructured":"Mademont-Soler I, et al. Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy. Plos One. 12(8):e0181465, https:\/\/doi.org\/10.1371\/journal.pone.0181465.","DOI":"10.1371\/journal.pone.0181465"},{"issue":"1","key":"382_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41436-018-0033-5","volume":"21","author":"R Truty","year":"2019","unstructured":"Truty R, Paul J, Kennemer M, et al. Prevalence and properties of intragenic copy-number variation in Mendelian disease genes. Genet Med. 2019;21(1):114\u201323. https:\/\/doi.org\/10.1038\/s41436-018-0033-5.","journal-title":"Genet Med"},{"issue":"6","key":"382_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2459\/JCM.0000000000001616","volume":"25","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Adamo M, Zou C, Porcari A, Tomasoni D, Rossi M, et al. Management of Hypertrophic Cardiomyopathy. J Cardiovasc Med. 2024;25(6):399\u2013419. https:\/\/doi.org\/10.2459\/JCM.0000000000001616.","journal-title":"J Cardiovasc Med"},{"issue":"44","key":"382_CR26","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","volume":"44","author":"E Braunwald","year":"2023","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: A First-in-Class Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy. Eur Heart J. 2023;44(44):4622\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehad637.","journal-title":"Eur Heart J"},{"issue":"4","key":"382_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2022;79(4):372\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.002.","journal-title":"J Am Coll Cardiol"},{"key":"382_CR28","doi-asserted-by":"publisher","first-page":"e037234","DOI":"10.1161\/JAHA.124.037234","volume":"14","author":"K Linden","year":"2025","unstructured":"Linden K, Green N, Muir A, Malcolmson JW, Mohiddin SA, O\u2019Mahony C. Size Matters: Prevalence and Clinical Implications of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy\u2014A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2025;14:e037234. https:\/\/doi.org\/10.1161\/JAHA.124.037234.","journal-title":"J Am Heart Assoc"},{"key":"382_CR29","doi-asserted-by":"publisher","unstructured":"Bernardini A, Crotti L, Olivotto I, Cecchi F. Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy.\u00a0Eur Heart J Suppl. 2023;25(Suppl C):C173-C178.\u00a0https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad074. Published 2023 Apr 26.","DOI":"10.1093\/eurheartjsupp\/suad074"},{"issue":"7","key":"382_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2019.12.030","volume":"75","author":"WY Ko","year":"2020","unstructured":"Ko WY, Siontis KC, Attia ZI, et al. Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. J Am Coll Cardiol. 2020;75(7):722\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.030.","journal-title":"J Am Coll Cardiol"},{"key":"382_CR31","doi-asserted-by":"publisher","unstructured":"Siontis KC, Wieczorek MA, Maanja M, et al. Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study.\u00a0Eur Heart J Digit Health. 2024;5(4):416\u2013426.\u00a0https:\/\/doi.org\/10.1093\/ehjdh\/ztae029. Published 2024 Apr 15.","DOI":"10.1093\/ehjdh\/ztae029"},{"key":"382_CR32","doi-asserted-by":"publisher","unstructured":"Love CJ, Lampert J, Huneycutt D, et al. Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.\u00a0Heart. 2025;111(21):1029\u20131035.\u00a0https:\/\/doi.org\/10.1136\/heartjnl-2024-325608. Published 2025 Oct 14.","DOI":"10.1136\/heartjnl-2024-325608"},{"key":"382_CR33","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.amjcard.2023.10.081","volume":"212","author":"MR Abraham","year":"2024","unstructured":"Abraham MR, Abraham TP. Role of Imaging in the Diagnosis, Evaluation, and Management of Hypertrophic Cardiomyopathy. Am J Cardiol. 2024;212:S14\u201332. https:\/\/doi.org\/10.1016\/j.amjcard.2023.10.081.","journal-title":"Am J Cardiol"},{"issue":"6","key":"382_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.echo.2022.03.012","volume":"35","author":"SF Nagueh","year":"2022","unstructured":"Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A, et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022;35(6):533\u201369. https:\/\/doi.org\/10.1016\/j.echo.2022.03.012.","journal-title":"J Am Soc Echocardiogr"},{"key":"382_CR35","doi-asserted-by":"publisher","unstructured":"Writing Committee Members, Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25). https:\/\/doi.org\/10.1161\/CIR.0000000000000937.","DOI":"10.1161\/CIR.0000000000000937"},{"issue":"3","key":"382_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12574-020-00467-9","volume":"18","author":"L Mande\u015f","year":"2020","unstructured":"Mande\u015f L, Ro\u015fca M, Ciuperc\u0103 D, Popescu BA. The Role of Echocardiography for Diagnosis and Prognostic Stratification in Hypertrophic Cardiomyopathy. J Echocardiogr. 2020;18(3):137\u201348. https:\/\/doi.org\/10.1007\/s12574-020-00467-9.","journal-title":"J Echocardiogr"},{"key":"382_CR37","doi-asserted-by":"publisher","unstructured":"Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D\u2019Andrea A, Bruder O, Cosyns B, Davin L, Donal E, Freitas A, Habib G, Kitsiou A, Petersen SE, Schroeder S, Lancellotti P. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the european association of cardiovascular imaging endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280\u2013280. https:\/\/doi.org\/10.1093\/ehjci\/jeu291.","DOI":"10.1093\/ehjci\/jeu291"},{"issue":"12","key":"382_CR38","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.cjca.2016.06.014","volume":"32","author":"JD Windram","year":"2016","unstructured":"Windram JD, Dragelescu A, Benson L, Forsey J, Shariat M, Yoo S-J, et al. Myocardial Dimensions in Children With Hypertrophic Cardiomyopathy: A Comparison Between Echocardiography and Cardiac Magnetic Resonance Imaging. Can J Cardiol. 2016;32(12):1507\u201312. https:\/\/doi.org\/10.1016\/j.cjca.2016.06.014.","journal-title":"Can J Cardiol"},{"issue":"11","key":"382_CR39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.echo.2015.07.015","volume":"28","author":"M Ro\u015fca","year":"2015","unstructured":"Ro\u015fca M, C\u0103lin A, Beladan CC, Enache R, Mateescu AD, Gurzun M-M, et al. Right Ventricular Remodeling, Its Correlates, and Its Clinical Impact in Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2015;28(11):1329\u201338. https:\/\/doi.org\/10.1016\/j.echo.2015.07.015.","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"382_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0735-1097(88)90101-5","volume":"11","author":"WJ McKenna","year":"1988","unstructured":"McKenna WJ, Kleinebenne A, Nihoyannopoulos P, Foale R. Echocardiographic Measurement of Right Ventricular Wall Thickness in Hypertrophic Cardiomyopathy: Relation to Clinical and Prognostic Features. J Am Coll Cardiol. 1988;11(2):351\u20138. https:\/\/doi.org\/10.1016\/0735-1097(88)90101-5.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"382_CR41","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.amjcard.2007.05.061","volume":"100","author":"MS Maron","year":"2007","unstructured":"Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2007.05.061.","journal-title":"Am J Cardiol"},{"issue":"5","key":"382_CR42","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/echo.13878","volume":"35","author":"RM Inciardi","year":"2018","unstructured":"Inciardi RM, Galderisi M, Nistri S, Santoro C, Cicoira M, Rossi A. Echocardiographic Advances in Hypertrophic Cardiomyopathy: Three-dimensional and Strain Imaging Echocardiography. Echocardiography. 2018;35(5):716\u201326. https:\/\/doi.org\/10.1111\/echo.13878.","journal-title":"Echocardiography"},{"issue":"4","key":"382_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.echo.2012.12.015","volume":"26","author":"S-A Chang","year":"2013","unstructured":"Chang S-A, Kim H-K, Lee S-C, Kim E-Y, Hahm S-H, Kwon OM, et al. Assessment of Left Ventricular Mass in Hypertrophic Cardiomyopathy by Real-Time Three-Dimensional Echocardiography Using Single-Beat Capture Image. J Am Soc Echocardiogr. 2013;26(4):436\u201342. https:\/\/doi.org\/10.1016\/j.echo.2012.12.015.","journal-title":"J Am Soc Echocardiogr"},{"issue":"10","key":"382_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1161\/CIRCULATIONAHA.121.058696","volume":"146","author":"S Goto","year":"2022","unstructured":"Goto S, Solanki D, John JE, et al. Multinational Federated Learning Approach to Train ECG and Echocardiogram Models for Hypertrophic Cardiomyopathy Detection. Circulation. 2022;146(10):755\u201369. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058696.","journal-title":"Circulation"},{"issue":"5","key":"382_CR45","doi-asserted-by":"publisher","first-page":"e017436","DOI":"10.1161\/CIRCIMAGING.124.017436","volume":"18","author":"I Moon","year":"2025","unstructured":"Moon I, Lee J, Lee SA, et al. Artificial Intelligence-Enhanced Analysis of Echocardiography-Based Radiomic Features for Myocardial Hypertrophy Detection and Etiology Differentiation. Circ Cardiovasc Imaging. 2025;18(5):e017436. https:\/\/doi.org\/10.1161\/CIRCIMAGING.124.017436.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"382_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.amjcard.2017.05.039","volume":"120","author":"H Liu","year":"2017","unstructured":"Liu H, Pozios I, Haileselassie B, Nowbar A, Sorensen LL, Phillip S, et al. Role of Global Longitudinal Strain in Predicting Outcomes in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(4):670\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.039.","journal-title":"Am J Cardiol"},{"issue":"6","key":"382_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ehjci\/jew005","volume":"17","author":"TF Haland","year":"2016","unstructured":"Haland TF, Almaas VM, Hasselberg NE, et al. Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2016;17(6):613\u201321. https:\/\/doi.org\/10.1093\/ehjci\/jew005.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"382_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12574-020-00508-3","volume":"19","author":"H Tanaka","year":"2021","unstructured":"Tanaka H. Efficacy of Echocardiography for Differential Diagnosis of Left Ventricular Hypertrophy: Special Focus on Speckle-Tracking Longitudinal Strain. J Echocardiogr. 2021;19(2):71\u20139. https:\/\/doi.org\/10.1007\/s12574-020-00508-3.","journal-title":"J Echocardiogr"},{"issue":"11","key":"382_CR49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.echo.2025.07.007","volume":"38","author":"JD Thomas","year":"2025","unstructured":"Thomas JD, Edvardsen T, Abraham T, et al. Clinical Applications of Strain Echocardiography: A Clinical Consensus Statement From the American Society of Echocardiography Developed in Collaboration With the European Association of Cardiovascular Imaging of the European Society of Cardiology. J Am Soc Echocardiogr. 2025;38(11):985\u20131020. https:\/\/doi.org\/10.1016\/j.echo.2025.07.007.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"382_CR50","doi-asserted-by":"publisher","first-page":"e70368","DOI":"10.1111\/echo.70368","volume":"43","author":"S Alnaimat","year":"2026","unstructured":"Alnaimat S, Mascara M, Pulipati Y, et al. Case series of the \u201cBlueberry-on-Top\u201d phenomenon: a recently recognized strain pattern in patients with apical variant hypertrophic cardiomyopathy. Echocardiography. 2026;43(1):e70368. https:\/\/doi.org\/10.1111\/echo.70368.","journal-title":"Echocardiography"},{"issue":"9","key":"382_CR51","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.echo.2017.05.017","volume":"30","author":"A Tower-Rader","year":"2017","unstructured":"Tower-Rader A, Betancor J, Lever HM, Desai MY. A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease. J Am Soc Echocardiogr. 2017;30(9):829\u201344. https:\/\/doi.org\/10.1016\/j.echo.2017.05.017.","journal-title":"J Am Soc Echocardiogr"},{"key":"382_CR52","doi-asserted-by":"publisher","unstructured":"P\u00e1link\u00e1s ED, Re F, Peteiro J, Tesic M, P\u00e1link\u00e1s A, Torres MAR, Dikic AD, Beleslin B, Van De Heyning CM, D\u2019Alfonso MG, Mori F, Ciampi Q, De Castro Silva Pretto JL, Simova I, Nagy V, Boda K, Sepp R, Olivotto I, Pellikka PA, Picano E. Pulmonary congestion during exercise stress echocardiography in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2022;38(12):2593\u20132604. https:\/\/doi.org\/10.1007\/s10554-022-02620-0.","DOI":"10.1007\/s10554-022-02620-0"},{"issue":"10","key":"382_CR53","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.echo.2024.06.011","volume":"37","author":"D Massera","year":"2024","unstructured":"Massera D, Long C, Xia Y, et al. Unmasking Obstruction in Hypertrophic Cardiomyopathy With Postprandial Resting and Treadmill Stress Echocardiography. J Am Soc Echocardiogr. 2024;37(10):971\u201380. https:\/\/doi.org\/10.1016\/j.echo.2024.06.011.","journal-title":"J Am Soc Echocardiogr"},{"issue":"23","key":"382_CR54","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.jacc.2008.10.001","volume":"52","author":"CA Warnes","year":"2008","unstructured":"Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, et al. ACC\/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2008;52(23):e143\u2013263. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.001.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"382_CR55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","volume":"38","author":"SF Nagueh","year":"2025","unstructured":"Nagueh SF, Sanborn DY, Oh JK, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J Am Soc Echocardiogr. 2025;38(7):537\u201369. https:\/\/doi.org\/10.1016\/j.echo.2025.03.011.","journal-title":"J Am Soc Echocardiogr"},{"key":"382_CR56","doi-asserted-by":"publisher","unstructured":"Lee H-J, Kim H-K, Rhee T-M, Choi Y-J, Hwang I-C, Yoon YE, Park J-B, Lee S-P, Kim Y-J, Cho G-Y. Left atrial reservoir strain-based left ventricular diastolic function grading and incident heart failure in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2022;15(4). https:\/\/doi.org\/10.1161\/CIRCIMAGING.121.013556.","DOI":"10.1161\/CIRCIMAGING.121.013556"},{"issue":"1","key":"382_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12947-025-00343-5","volume":"23","author":"P Francesca","year":"2025","unstructured":"Francesca P, Eluisa LF, Lorenzo P, Giovanni G, Diego B, Vincenzo N, et al. The Role of Left Atrio-Ventricular Coupling Index and Left Atrial Ejection Fraction in Predicting Onset of Atrial Fibrillation and Adverse Cardiac Events in Hypertrophic Cardiomyopathy. Cardiovasc Ultrasound. 2025;23(1):10. https:\/\/doi.org\/10.1186\/s12947-025-00343-5.","journal-title":"Cardiovasc Ultrasound"},{"issue":"7","key":"382_CR58","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jcmg.2016.05.003","volume":"9","author":"BJ Maron","year":"2016","unstructured":"Maron BJ, Maron MS. The Remarkable 50 Years of Imaging in HCM and How it Has Changed Diagnosis and Management: From M-Mode Echocardiography to CMR. JACC Cardiovasc Imaging. 2016;9(7):858\u201372. https:\/\/doi.org\/10.1016\/j.jcmg.2016.05.003.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"382_CR59","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","volume":"6","author":"RB Thompson","year":"2013","unstructured":"Thompson RB, Chow K, Khan A, et al. T\u2081 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013;6(5):637\u201345. https:\/\/doi.org\/10.1161\/CIRCIMAGING.113.000482.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"382_CR60","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.echo.2023.04.020","volume":"36","author":"CC Mitchell","year":"2023","unstructured":"Mitchell CC, Frye C, Jankowski M, Symanski J, Lester SJ, Woo A, et al. A Practical Approach to Echocardiographic Imaging in Patients With Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2023;36(9):913\u201332. https:\/\/doi.org\/10.1016\/j.echo.2023.04.020.","journal-title":"J Am Soc Echocardiogr"},{"key":"382_CR61","doi-asserted-by":"publisher","unstructured":"Aquaro GD, Guidi B, Biondi F, et al. Post-Mortem Cardiac Magnetic Resonance for the Diagnosis of Hypertrophic Cardiomyopathy.\u00a0Diagnostics (Basel). 2020;10(11):981.\u00a0https:\/\/doi.org\/10.3390\/diagnostics10110981. Published 2020 Nov 21.","DOI":"10.3390\/diagnostics10110981"},{"issue":"10","key":"382_CR62","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/CIRCULATIONAHA.111.089409","volume":"126","author":"TC Wong","year":"2012","unstructured":"Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126(10):1206\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.089409.","journal-title":"Circulation"},{"issue":"7","key":"382_CR63","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1007\/s00330-020-07650-7","volume":"31","author":"Y Li","year":"2021","unstructured":"Li Y, Liu X, Yang F, et al. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy. Eur Radiol. 2021;31(7):4557\u201367. https:\/\/doi.org\/10.1007\/s00330-020-07650-7.","journal-title":"Eur Radiol"},{"issue":"1","key":"382_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.diii.2025.09.001","volume":"107","author":"C Gkizas","year":"2026","unstructured":"Gkizas C, Longere B, Bechrouri S, et al. Photon-counting CT myocardial extracellular volume: A non-invasive biomarker for fibrosis in patients with hypertrophic cardiomyopathy. Diagn Interv Imaging. 2026;107(1):17\u201324. https:\/\/doi.org\/10.1016\/j.diii.2025.09.001.","journal-title":"Diagn Interv Imaging"},{"key":"382_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1714\/4100.40979","volume":"24","author":"A Argir\u00f2","year":"2023","unstructured":"Argir\u00f2 A, Zampieri M, Marchi A, Del Franco A, P\u00e0link\u00e0s ED, Biagioni G, et al. Approcci Terapeutici nella Cardiomiopatia Ipertrofica: Dal Controllo dei Sintomi alla Terapia di Precisione. G Ital Cardiol. 2023;24:1\u201310. https:\/\/doi.org\/10.1714\/4100.40979.","journal-title":"G Ital Cardiol"},{"issue":"12","key":"382_CR66","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/eurjpc\/zwae198","volume":"32","author":"G Halasz","year":"2025","unstructured":"Halasz G, Dei LL, Moroni F, Ayers MP, Ciacci P, Giacalone G, et al. The Impact of Disopyramide on Exercise Capacity among Patients with Obstructive Hypertrophic Cardiomyopathy: Beyond Left Ventricular Outflow Tract Gradient. Eur J Prev Cardiol. 2025;32(12):1122\u20134. https:\/\/doi.org\/10.1093\/eurjpc\/zwae198.","journal-title":"Eur J Prev Cardiol"},{"issue":"10253","key":"382_CR67","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"issue":"20","key":"382_CR68","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024;390(20):1849\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2401424.","journal-title":"N Engl J Med"},{"issue":"11","key":"382_CR69","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","volume":"147","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, et al. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Circulation. 2023;147(11):850\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062534.","journal-title":"Circulation"},{"key":"382_CR70","doi-asserted-by":"publisher","unstructured":"Desai MY, Wolski K, Owens A, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, Gong Z, Mudarris L, Lampl K, Sehnert AJ, Nissen SE, for the VALOR-HCM Investigators. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation. 2025;151(19):1378\u20131390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072445.","DOI":"10.1161\/CIRCULATIONAHA.124.072445"},{"issue":"6","key":"382_CR71","doi-asserted-by":"publisher","first-page":"e038758","DOI":"10.1161\/JAHA.124.038758","volume":"14","author":"BJ Davis","year":"2025","unstructured":"Davis BJ, Volk H, Nguyen O, et al. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2025;14(6):e038758. https:\/\/doi.org\/10.1161\/JAHA.124.038758.","journal-title":"J Am Heart Assoc"},{"key":"382_CR72","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pe\u00f1a-Pe\u00f1a ML, Barriales-Villa R, et al. for the MAPLE-HCM Investigators. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy. N Engl J Med. 2025;393:949\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2504654.","DOI":"10.1056\/NEJMoa2504654"},{"issue":"1","key":"382_CR73","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ccl.2018.08.008","volume":"37","author":"TC Wong","year":"2019","unstructured":"Wong TC, Martinez M. Novel Pharmacotherapy for Hypertrophic Cardiomyopathy. Cardiol Clin. 2019;37(1):113\u20137. https:\/\/doi.org\/10.1016\/j.ccl.2018.08.008.","journal-title":"Cardiol Clin"},{"issue":"5","key":"382_CR74","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","volume":"127","author":"R Coppini","year":"2013","unstructured":"Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, et al. Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy. Circulation. 2013;127(5):575\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.134932.","journal-title":"Circulation"},{"issue":"16","key":"382_CR75","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","volume":"68","author":"JL Gentry","year":"2016","unstructured":"Gentry JL, Mentz RJ, Hurdle M, Wang A. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2016.07.758.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"382_CR76","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCRESAHA.117.312647","volume":"122","author":"AJ Marian","year":"2018","unstructured":"Marian AJ, Tan Y, Li L, Chang J, Syrris P, Hessabi M, et al. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled. Double-Blind Pilot Study Circ Res. 2018;122(8):1109\u201318. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.312647.","journal-title":"Double-Blind Pilot Study Circ Res"},{"issue":"17","key":"382_CR77","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","volume":"79","author":"H Cui","year":"2022","unstructured":"Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, et al. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2022;79(17):1647\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.032.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"382_CR78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12055-019-00817-y","volume":"36","author":"JH Hong","year":"2020","unstructured":"Hong JH, Nguyen A, Schaff HV. Management of the mitral valve in patients with obstructive hypertrophic cardiomyopathy. Indian J Thorac Cardiovasc Surg. 2020;36(Suppl 1):34\u201343. https:\/\/doi.org\/10.1007\/s12055-019-00817-y.","journal-title":"Indian J Thorac Cardiovasc Surg"},{"issue":"1","key":"382_CR79","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jtcvs.2020.12.143","volume":"165","author":"J Lentz Carvalho","year":"2023","unstructured":"Lentz Carvalho J, Schaff HV, Nishimura RA, et al. Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy? J Thorac Cardiovasc Surg. 2023;165(1):79-87.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2020.12.143.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"382_CR80","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.jtcvs.2025.03.032","volume":"170","author":"Y Qamar","year":"2025","unstructured":"Qamar Y, Schaff HV, Geske JB, et al. Durability of mitral valve repair for degenerative mitral valve disease in patients with obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2025;170(6):1621-1630.e5. https:\/\/doi.org\/10.1016\/j.jtcvs.2025.03.032.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"382_CR81","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jchf.2014.06.012","volume":"2","author":"PA Vriesendorp","year":"2014","unstructured":"Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AFL, Willems R, Ten Cate FJ, et al. Long-Term Outcomes After Medical and Invasive Treatment in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail. 2014;2(6):630\u20136. https:\/\/doi.org\/10.1016\/j.jchf.2014.06.012.","journal-title":"JACC Heart Fail"},{"issue":"24","key":"382_CR82","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.jacc.2016.03.587","volume":"67","author":"P Sorajja","year":"2016","unstructured":"Sorajja P, Pedersen WA, Bae R, Lesser JR, Jay D, Lin D, et al. First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016;67(24):2811\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.587. PMID: 27311518.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"382_CR83","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jcin.2025.10.013","volume":"19","author":"L Testa","year":"2026","unstructured":"Testa L, Arzuffi L, Popolo Rubbio A, et al. Transcatheter Edge-to-Edge Repair for SAM-Related Mitral Regurgitation in Patients With HCM: The TRANSPARENT Registry. J Am Coll Cardiol Intv. 2026;19(5):604\u201314. https:\/\/doi.org\/10.1016\/j.jcin.2025.10.013.","journal-title":"J Am Coll Cardiol Intv"},{"issue":"16","key":"382_CR84","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.jacc.2018.07.080","volume":"72","author":"L Liu","year":"2018","unstructured":"Liu L, Li J, Zuo L, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol. 2018;72(16):1898\u2013909. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.080.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"382_CR85","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamacardio.2022.0259","volume":"7","author":"M Zhou","year":"2022","unstructured":"Zhou M, Ta S, Hahn RT, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy. JAMA Cardiol. 2022;7(5):529\u201338. https:\/\/doi.org\/10.1001\/jamacardio.2022.0259.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"382_CR86","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.21037\/atm-21-2783","volume":"9","author":"L Kong","year":"2021","unstructured":"Kong L, Zhao Y, Pan H, Ma J, Qian J, Ge J. A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series. Ann Transl Med. 2021;9(12):1006. https:\/\/doi.org\/10.21037\/atm-21-2783.","journal-title":"Ann Transl Med"},{"issue":"5","key":"382_CR87","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jacc.2010.07.055","volume":"57","author":"T Lawrenz","year":"2011","unstructured":"Lawrenz T, Borchert B, Leuner C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months\u2019 follow-up in 19 patients. J Am Coll Cardiol. 2011;57(5):572\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2010.07.055.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"382_CR88","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jchf.2023.07.004","volume":"11","author":"LW Liang","year":"2023","unstructured":"Liang LW, Lumish HS, Sewanan LR, et al. Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy: State-of-the-Art Review and an Updated Analysis From UNOS. JACC Heart Fail. 2023;11(11):1473\u201380. https:\/\/doi.org\/10.1016\/j.jchf.2023.07.004.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"382_CR89","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","volume":"5","author":"I Olivotto","year":"2012","unstructured":"Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5(4):535\u201346. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.967026.","journal-title":"Circ Heart Fail"},{"issue":"17","key":"382_CR90","doi-asserted-by":"publisher","first-page":"e039551","DOI":"10.1161\/JAHA.124.039551","volume":"14","author":"I Landsteiner","year":"2025","unstructured":"Landsteiner I, Masri A, Saberi S, et al. Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta-Analysis. J Am Heart Assoc. 2025;14(17):e039551. https:\/\/doi.org\/10.1161\/JAHA.124.039551.","journal-title":"J Am Heart Assoc"},{"key":"382_CR91","doi-asserted-by":"publisher","unstructured":"Di Fiore V, Del Punta L, De Biase N, et al. Advancing Cardiovascular Risk Stratification and Functional Assessment: A Narrative Review of CPET and ESE Applications.\u00a0Healthcare (Basel). 2025;13(13):1627.\u00a0https:\/\/doi.org\/10.3390\/healthcare13131627. Published 2025 Jul 7.","DOI":"10.3390\/healthcare13131627"},{"issue":"12","key":"382_CR92","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cardfail.2017.09.011","volume":"23","author":"SR Patel","year":"2017","unstructured":"Patel SR, Saeed O, Naftel D, et al. Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. J Card Fail. 2017;23(12):859\u201367. https:\/\/doi.org\/10.1016\/j.cardfail.2017.09.011.","journal-title":"J Card Fail"},{"key":"382_CR93","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2022.12.056","volume":"374","author":"M Zampieri","year":"2023","unstructured":"Zampieri M, Salvi S, Fumagalli C, et al. Clinical scenarios of hypertrophic cardiomyopathy-related mortality: Relevance of age and stage of disease at presentation. Int J Cardiol. 2023;374:65\u201372. https:\/\/doi.org\/10.1016\/j.ijcard.2022.12.056.","journal-title":"Int J Cardiol"},{"issue":"36","key":"382_CR94","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"2","key":"382_CR95","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/ejhf\/xuaf008","volume":"28","author":"B Meder","year":"2026","unstructured":"Meder B. Caroline J Coats, Leslie A Leinwand, Maurizio Pieroni, Pablo Garcia-Pavia, Milind Y Desai, Farbod Sedaghat-Hamedani, EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy. Eur J Heart Fail. 2026;28(2):299\u2013314. https:\/\/doi.org\/10.1093\/ejhf\/xuaf008.","journal-title":"Eur J Heart Fail"},{"key":"382_CR96","doi-asserted-by":"publisher","unstructured":"Rodrigues T, Raposo SC, Brito D, Lopes LR. Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review. Int J Cardiol. 2021;339:83\u201392. https:\/\/doi.org\/10.1016\/j.ijcard.2021.06.051. Epub 2021 Jun 30. PMID: 34214502; PMCID: PMC8425182.","DOI":"10.1016\/j.ijcard.2021.06.051"},{"issue":"2","key":"382_CR97","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCULATIONAHA.123.065987","volume":"149","author":"CC Topriceanu","year":"2024","unstructured":"Topriceanu CC, Pereira AC, Moon JC, Captur G, Ho CY. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation. 2024;149(2):107\u201323. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065987.","journal-title":"Circulation"},{"key":"382_CR98","doi-asserted-by":"publisher","unstructured":"Menezes Junior ADS, de Oliveira HL, de Lima KBA, Botelho SM, Wastowski IJ. T-Cell-Driven Immunopathology and Fibrotic Remodeling in Hypertrophic Cardiomyopathy: A Translational Scoping Review.\u00a0Cells. 2025;15(1):61.\u00a0https:\/\/doi.org\/10.3390\/cells15010061. Published 2025 Dec 29.","DOI":"10.3390\/cells15010061"}],"container-title":["Cardiovascular Ultrasound"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12947-026-00382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12947-026-00382-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12947-026-00382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:02:10Z","timestamp":1789340530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12947-026-00382-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1186\/s12947-026-00382-6","relation":{},"ISSN":["1476-7120"],"issn-type":[{"value":"1476-7120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}